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Background: Unintentional weight loss occurs among advanced non-small-cell lung cancer (NSCLC) patients and is asso-
ciated with worse survival. Small studies have suggested that weight gain during treatment is associated with superior survival.
Patients and methods: A retrospective analysis analyzed data from three international phase III studies comprising
2301 advanced, non-squamous NSCLC patients who received a platinum-based, first-line doublet, with or without beva-
cizumab and maintenance therapy. Body weight was recorded before and after treatment by each study’s schedule. The
relationship between weight gain and overall survival (OS) and progression-free survival (PFS) was assessed using log-
rank test and adjusted Cox modeling. Logistic regression assessed the association between baseline covariates and
post-baseline weight gain.
Results: Four hundred and twenty-one (18.3%) patients had >5% weight gain after baseline. More than half of the
weight gain cohort exhibited initial weight gain by 3 weeks. The median OS was 16.7 months versus 10.7 months for the
>5% versus ≤5% weight gain subgroup (n = 1880) (P < 0.001). PFS was 6.9 versus 4.8 months, respectively (P < 0.001).
Differences in overall tumor response rate (50.8% versus 25.4%, respectively) and disease control rate (tumor response
or stable disease) (91.5% versus 63.6%, respectively) were also significant (P < 0.001). The Cox modeling revealed the
>5% subgroup had longer survival [hazard ratio (HR) = 0.54, 95% confidence interval (CI) 0.47–0.62; P < 0.001] than the
≤5% subgroup after adjusting for baseline factors. Similar significant results were found for PFS (HR = 0.59, 95% CI
0.52–0.67; P < 0.001). Unadjusted logistic regression indicated a significant association between weight gain
(>5% versus ≤5%) and age, and BMI.
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Conclusions: Weight gain during treatment may be an early indicator of clinical benefit. If confirmed in prospective
studies, monitoring weight change may provide important information regarding survival outcomes in NSCLC and may
provide ideas for new therapeutic strategies.
Key words: NSCLC, weight gain, retrospective analysis, phase III clinical trial, cachexia
introduction
Lung cancer represents ∼13% of the global cancer burden [1];
the mortality rate is among the highest of all cancers, in part due
to the late stage at diagnosis [1]. Performance status and disease
stage are two well-established non-small-cell lung cancer
(NSCLC) prognostic factors [2, 3]. The loss of appetite and
weight loss at presentation have also been identified as adverse
prognostic factors in some advanced NSCLC studies [2, 4–8].
A retrospective analysis of lung cancer patients at diagnosis
reported ∼60% of patients had already experienced weight loss
[6]. Whether weight loss continued or stabilized during therapy
correlated with progression-free survival (PFS) and overall sur-
vival (OS). NSCLC patients with weight stabilization experienced
2 months longer median PFS (P = 0.01) and OS (P = 0.006). Two
small retrospective studies of locally advanced NSCLC patients
showed that weight gain was associated with superior survival
[9, 10]. Similarly, in a larger retrospective study, patients with
stage III NSCLC who maintained or gained weight after chemora-
diation survived significantly longer [11]. The investigators sug-
gested future study of weight loss during treatment might provide
the basis for new treatment strategies for patients with stage III
NSCLC. The objective of our study was to evaluate potential rela-
tionships between serial weight changes and outcomes in patients
with advanced non-squamous NSCLC treated with chemother-
apy. Our analyses focused on weight gain defined as >5% post-
baseline since prior studies of the prognostic impact of weight
loss have used this threshold [3, 4], and since higher thresholds
(10%, 15%) result in too few patients.
methods
patients and study design
Patients included in these retrospective analyses had stage IIIB or IV NSCLC
and had received a platinum doublet, with or without bevacizumab, as first-line
treatment in one of three phase III clinical trials: JMDB (pemetrexed/cisplatin
versus gemcitabine/cisplatin) [12]; S380 (pemetrexed/carboplatin versus doce-
taxel/carboplatin) [13]; and PointBreak (JMHD) (carboplatin/pemetrexed/beva-
cizumab followed by maintenance pemetrexed/bevacizumab versus carboplatin/
paclitaxel/bevacizumab followed by maintenance bevacizumab) [14].
The analysis set met the following criteria: (i) non-squamous NSCLC
confirmed by histology data; (ii) received at least one dose of treatment; (iii)
had at least one recorded pretreatment and post-treatment body weight; (iv)
available survival data. Patients excluded from the analyses for reasons of
histology or treatment are summarized (supplementary Appendix Table SA,
available at Annals of Oncology online). Overall, a total of 2301 treated
non-squamous patients were included in the pooled analysis set: JMDB trial,
n = 1208; S380 trial, n = 209; PointBreak trial, n = 884. To maximize the size
of the analysis set, all analyses used the three-trial pooled analysis set with
the exception of time-to-weight-gain analysis (Table 1); there, Pointbreak
data were presented separately due to a salient difference in study design.
baseline and treatment assessments
Efficacy measures included OS, PFS, and best overall tumor response (per
RECIST 1.0 guidelines). In general, body weight was recorded at baseline, at
the onset of every treatment cycle, and at the 30-day post-study discontinu-
ation follow-up visit.
statistical analyses
Baseline body weight was defined as the last non-missing weight measure
before first treatment. Post-baseline body weight was defined as the maximum
weight during treatment or at the 30-day post-study discontinuation follow-up
visit. The analysis set was divided into two groups: those with >5% weight
gain and those with ≤5% weight gain. Unadjusted logistic regression was
used to assess the association between baseline covariates and post-baseline
weight gain.
Patient data were analyzed using graphs of the Kaplan–Meier estimates,
log-rank test, and adjusted Cox modeling to assess the relationship between
weight gain and OS and PFS. Fisher’s exact test was used to compare the
overall response rate (ORR, percentage of patients with either a complete or
partial tumor response) and disease control rate (DCR, percentage of patients
with either stable disease or a tumor response) between weight gain groups.
Adjusted logistic regression was used to assess the relationship between weight
gain and ORR and DCR. Patients without smoking status at baseline (n = 148)
were excluded from the adjusted Cox and logistic modeling.
As an exploratory BMI analysis, we categorized patients into six mutually
exclusive groups based on their baseline BMI and post-baseline weight gain,
and investigated the impact on OS using the Kaplan–Meier estimates, the
log-rank test, and adjusted Cox modeling.
SAS (Version 9.2, SAS Institute, Cary, NC) was used for all analyses. All
the statistical tests were two-sided. A P-value of 0.05 was the statistical
significance threshold.
results
Patient demographics are reported (supplementary Appendix
Table SB, available at Annals of Oncology online). A total of 421
patients (18%) had a >5% increase in weight (‘>5% subgroup’)
over baseline weight measurement at ≥1 time point during the
study. Among those patients achieving >5% weight gain in the
analysis set derived from studies S380 and JMDB, two-thirds
(67.8%) of them achieved this threshold after 9 weeks of treat-
ment (Table 1). In the PointBreak study in which all patients
were randomized to induction therapy and eligible patients con-
tinued to maintenance therapy after four cycles of induction
therapy, approximately half (54.0%) of the patients who
achieved >5% weight gain did so after 12 weeks of treatment
(4 induction cycles). A similar analysis examined when >5%
subgroup patients reached their maximum post-baseline weight
(Table 1).
Unadjusted logistic regression indicated a significant associ-
ation between weight gain (>5% versus ≤5%) and age and BMI,
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among baseline covariates. More patients aged <65, or with a
BMI ≤25 had a >5% weight gain (P < 0.001) after treatment. In
addition, there was no significant weight gain association
(P = 0.983) between patients with a BMI <20 and those with a
BMI between 20 and 25.
The >5% weight gain subgroup from the three study pooled
analysis set exhibited a median OS of 16.7 months versus the
median OS in the ≤5% weight gain subgroup (‘≤5% subgroup’)
of 10.7 months [P < 0.001; unadjusted hazard ratio (HR) = 0.57,
95% confidence interval (CI) 0.50–0.65] (Figure 1A). An add-
itional analysis using ‘any weight gain’ rather than 5% as the
cutoff (1066 of the 2301 patients in this group) found similar
results (median OS = 15.2 and 8.6 months, respectively;
HR = 0.51, 95% CI 0.46–0.56).
The median PFS was also statistically longer for the >5% sub-
group (6.9 versus 4.8 months, P < 0.001; unadjusted HR = 0.61,
95% CI 0.55–0.69) (Figure 1B). When the analysis was repeated
for the three-trial intent-to-treat (randomized) population
(n = 2924, supplementary Appendix Table SA, available at
Annals of Oncology online), near identical results were obtained
(data not shown).
There was also a statistically significant difference between the
ORR and DCR of the >5% subgroup and that of the ≤5%
subgroup. (50.8% versus 25.4%, P < 0.001; 91.5% versus 63.6%,
P < 0.001) (Table 2).
Adjusted Cox modeling revealed that patients in the >5% sub-
group had significantly longer survival (HR = 0.54, 95% CI
0.47–0.62; P < 0.001) than those in the ≤5% subgroup, after
adjusting for baseline age (<65 versus ≥65), sex, ECOG PS
(0 versus 1/2), histology (adenocarcinoma versus others),
disease stage (IIIB versus IV), smoking (yes versus no), BMI
(<20, 20–25, >25), and study. Similar significant results were
found for PFS, with patients in the >5% subgroup exhibiting sig-
nificantly longer PFS (HR = 0.59, 95% CI 0.52–0.67; P < 0.001)
than those in the ≤5% subgroup after adjusting for the other
covariates.
Except for age in the OS model and sex in the PFS model,
all other baseline covariates were identified as significant prog-
nostic factors for survival outcomes, after adjusting for
other covariates in the model. For BMI, the group of BMI >25
had significantly longer OS and PFS than the other two BMI
groups.
Table 1. Timing of the earliest and maximum post-baseline patient weight gain
Cycle number at
which weight was
recordeda
Weeks of treatment
preceding measuring
weight
Timing at which earliest >5% post-
baseline patient weight gain
observed
Timing at which maximum post-baseline
weight gain observed among patients
achieving >5% weight gain
Cumulative
frequency
Cumulative
percent
Cumulative
frequency
Cumulative percent
Combined JMDB and S380 trial patients (n = 1417)b
2 3 36 14.0 17 6.6
3 6 95 36.8 37 14.3
4 9 175 67.8 78 30.2
5 12 221 85.7 139 53.9
6 15 251 97.3 240 93.0
Post-study 19c 258 100 258 100
PointBreak (JMHD) trial patients (n = 884)b
2 3 7 4.3 3 1.8
3 6 42 25.8 10 6.1
4 9 74 45.4 25 15.3
501 12 88 54.0 32 19.6
502 15 106 65.0 44 27.0
503 18 120 73.6 56 34.4
504 21 127 77.9 78 47.9
505 24 140 85.9 95 58.3
506 27 149 91.4 110 67.5
507 30 152 93.3 118 72.4
508 33 155 95.1 125 76.7
509–532 ≥36 163 100 163 100
aWeight was recorded at the beginning of each scheduled 3-week cycle. Baseline weight was defined as the last non-missing weight measure before first
treatment at cycle 1.
bData from PointBreak are presented separately from JMDB and S380 because the study was structured differently. Patients participating in the JMDB and
S380 studies received the same treatment for up to six 3-week cycles. PointBreak patients received four 3-week cycles of induction therapy (cycles 1–4), and
then the eligible patients continued to receive 3-week cycles of maintenance therapy until progressive disease or treatment discontinuation. PointBreak
maintenance cycles are designated 501, 502, and so on, beginning with the first maintenance cycle.
cWeight was recorded during the 30-day (∼4 weeks) post-final treatment visit for the S380 trial patients. There was no corresponding time point for JMDB
trial patients.
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The Forest plot (Figure 2) demonstrates the median OS differ-
ences between patients with or without a >5% weight gain by
baseline characteristics (age, sex, histology type, ECOG PS,
disease stage, smoking history, BMI, and study). The plot shows
the statistically significant improvement in survival with weight
gain in all subgroups.
Logistic regression models with multiple covariates were used
to ascertain if patients displaying weight gain were more or less
likely to display a tumor response or disease control. Adjusting
for the baseline covariates (age, gender, non-squamous histology
type, ECOG PS, stage, smoking history, BMI, and study),
patients in the >5% subgroup were significantly more likely to
exhibit a complete or partial tumor response (OR = 2.55, 95%
CI 2.02–3.22; P < 0.001) and disease control (CR + PR + SD)
(OR = 4.28, 95% CI 2.89–6.35; P < 0.001).
For the exploratory BMI analysis, patients were grouped
based on their baseline BMI and post-baseline weight gain
status: BMI >25 and weight gain >5% (n = 144, median
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Figure 1. Graphs of the Kaplan–Meier estimates of (A) overall survival and (B) progression-free survival by >5% weight gain and ≤5% weight gain in the
three-trial non-squamous analysis set. CI, confidence interval; HR, hazard ratio; n, number of patients; mOS, median overall survival (months); mPFS, median
progression-free survival (months).
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OS = 20.6 months, 95% CI 17.08–26.78); 20≤ BMI ≤ 25 and
weight gain >5% (n = 214, median OS = 14.7 months, 95% CI
13.86–17.74); BMI <20 and weight gain >5% (n = 63, median
OS = 15.7 months, 95% CI 10.32–16.99); BMI >25 and weight
gain ≤5% (n = 941, median OS = 11.6 months, 95% CI 10.78–
12.42); 20≤ BMI≤ 25 and weight gain ≤5% (n = 726, median
OS = 10.2 months, 95% CI 9.4–11.27); and BMI <20 and weight
gain ≤5% (n = 213, median OS = 7.8 months, 95% CI 6.28–
9.63). The log-rank tests show that the group of BMI >25 and
weight gain >5% had significantly longer survival than other
groups. In an adjusted Cox model with the BMI by weight gain
group included as a categorical variable, this group variable was
shown to be a significant factor for OS (P < 0.001), after adjust-
ing for baseline covariates (age, sex, histology type, ECOG PS,
disease stage, smoking history, and study). Moreover, the group
BMI >25 and weight gain >5% had significantly longer survival
than other BMI and weight gain groups, after adjusting for
baseline covariates.
discussion
In this retrospective study, weight gain during chemotherapy
was compared with outcomes in patients with advanced non-
squamous NSCLC using pooled data from three phase III
clinical trials. A weight gain of >5% occurred after initiation of
platinum-based chemotherapy in 18% of patients (421 patients).
This subgroup of patients exhibited a positive correlation
between weight gain and improved OS, PFS, and tumor re-
sponse. Although this association was also observed when
weight gain was defined as ‘any weight gain’ (rather than >5%),
our analyses focused on patients with >5% weight gain since the
lower cutoff likely includes patients with small increases in
weight due to daily fluctuations in hydration and standard error
variances.
Weight loss exhibited by cancer patients may be due to the
physical inability to ingest or digest food (e.g. due to nausea).
However, across all types of cancer, associated weight loss is
more frequently an outcome of cachexia syndrome, that is, the
cancer-induced metabolic shift that results in an involuntary
loss of body mass (fat and muscle) that cannot be reversed nu-
tritionally [15]. This metabolic shift is characterized by
increased lipolysis and alterations in skeletal muscle metabolism
including increased resting energy expenditure, decreased
protein synthesis, and increased protein degradation [15].
Patients also exhibit hypoalbuminemia and evidence of inflam-
mation (e.g. elevated C-reactive protein). Cachexia decreases
patients’ quality of life, reduces physical activity, causes greater
susceptibility to infection, and is the cause of death in at least
20% of all cancer patients [16].
The association of weight gain with disease control and super-
ior survival suggests that treatment-induced tumor regression/
stabilization may inhibit molecular pathways involved in cach-
exia. This observation raises the possibility that therapeutic
strategies specifically targeting mechanisms of cachexia might
reduce tumor growth rate and prolong survival. Although previ-
ous nutritional and pharmacologic anti-cachexia interventions
have not been successful, there is increasing information regard-
ing the mechanisms that mediate cancer cachexia. Ongoing sar-
copenia, a dominant feature of cancer cachexia, serves as a
source of energy and molecules for synthesis of macromolecules
in tumors. Recently, anamorelin, a ghrelin agonist [17], and
enobosarm [18], a selective androgen receptor modulator, have
been shown to increase lean body mass in advanced lung cancer
patients. Evaluation of OS was not a primary end point on these
studies.
While the mechanisms that mediate cancer cachexia are in-
completely defined, substantial evidence suggests the involve-
ment of inflammatory cytokines released either by the tumor or
host inflammatory cells responding to the tumor [15, 16].
Table 2. Best overall response rate in the three-trial analysis set
Variable All combined All strata P-value*
All (n = 2301) >5% Gain (n = 421) ≤5% Gain (n = 1880)
Complete response (CR) (%)
95% CI
0.4
(0.2, 0.8)
0.7
(0.2, 2.1)
0.4
(0.2, 0.8)
Partial response (PR) (%)
95% CI
29.6
(27.8, 31.6)
50.1
(45.2, 55.0)
25.1
(23.1, 27.1)
Stable disease (SD) (%)
95% CI
38.6
(36.6, 40.6)
40.6
(35.9, 45.5)
38.1
(35.9, 40.4)
Progressive disease (%)
95% CI
19.4
(17.8, 21.1)
7.6
(5.3, 10.6)
22.1
(20.2, 24.0)
Unknown/missing (%)
95% CI
11.91
(10.6, 13.3)
1.0
(0.3, 2.4)
14.4
(12.8, 16.0)
ORR (CR + PR) (%)
95% CI
30.1
(28.2, 32.0)
50.8
(46.0, 55.7)
25.4
(23.5, 27.5)
<0.001
DCR (CR + PR + SD) (%)
95% CI
68.7
(66.7, 70.6)
91.5
(88.4, 93.9)
63.6
(61.3, 65.7)
<0.001
*P-value: Fisher’s exact test to compare >5% gain versus ≤5% gain.
CI, confidence interval; ORR, overall response rate; DCR, disease control rate.
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Tumor necrosis factor α (TNFα), interleukin-6 (IL-6), inter-
feron γ (IFNγ), and transforming growth factor β superfamily
member MIC-1/GDF15 have been implicated as cachexia med-
iators [15, 19, 20]. Interestingly, elevated levels of circulating in-
flammatory cytokines have also been shown to occur with age
[21, 22]. Specifically, elevated levels of TNFα, IL-6, and IL-1
have been associated with increased morbidity and mortality in
older patients, with TNFα and IL-6 markers of mortality in frail
elderly patients [22]. This higher basal level of inflammatory
cytokines in older patients may in part explain why the univari-
ate logistic regression analysis identified younger patients as
more likely to gain weight after treatment than older patients.
The positive association between younger age and gaining
weight observed in our Cox analyses does not necessarily mean
younger patients will also have a significantly better survival
outcome since there may be some interactive effect between age
and other covariates such as this low level elevation of inflam-
matory cytokines. Our logistic regression analysis also found
that patients with a better PS (0 versus 1/2) were more likely to
gain weight. A similar association was also found in a study in
which a heightened inflammatory response in advanced NSCLC
patients was accompanied by poorer performance status, greater
weight loss, and poorer survival [23]. Although our studies did
not collect samples required to study inflammatory cytokines,
future studies might explore their contribution to weight loss
and gain. Studies might also collect data on serum albumin
levels before and after chemotherapy to determine whether low
albumin is a predictive factor for chemotherapy benefit and risk
of toxicity. If albumin is a predictive factor for weight gain,
patients who have had greater weight loss, or weight loss over a
longer time period, might have lower albumin levels more sug-
gestive of cachexia than those with more normal albumin levels.
Our analyses of the non-squamous NSCLC patients found
similar HRs associated with all three BMI subgroups, suggesting
a similar survival advantage among individuals who gain
weight, independent of their initial weight. This included those
All patients (N = 2153)
Age ≥65 years (N = 846)
Age <65 years (N = 1307)
Male (N = 1267)
Female (N = 886)
Adenocarcinoma (N = 550)
NonSqu/Nonadeno/NOS (N = 1603)
ECOG PS 1 or 2 (N = 1317)
ECOG PS 0 (N = 836)
Stage IV NSCLC (N = 1791)
Stage IIIB NSCLC (N = 362)
Smoking no (N = 382)
Smoking yes (N = 1771)
0 < BMI < 20 (N = 257)
20 £ BMI £ 20 (N = 879)
BMI >25 (N = 1017)
JMDB (N = 1055)
S380 (N = 209)
POINTBREAK (N = 879)
0.3 0.6
Favors weight gain Favors no weight gain
0.43
0.77
0.58
0.47
0.61
0.48
0.54
0.52
0.71
0.51
0.58
0.52
0.53
0.55
0.49
0.56
0.51
0.59
0.54
Hazard ratio
0.9 1.2 1.5
Figure 2. Overall survival hazard ratios (>5% weight gain/≤5% weight gain) in subgroups according to baseline characteristics. Survival hazard ratios (weight
gain >5% versus weight gain ≤5%) are shown for subgroups of the analysis set as defined by baseline characteristics. Ninety-five percentage confidence intervals
are depicted; P-values are <0.001 except for the S380 subgroup (P = 0.019), stage IIIB subgroup (P = 0.047), and Smoking No (P = 0.002). This analysis used the
non-squamous-treated patient set used by other analyses, but excluded 148 patients who did not have smoking status at baseline. For each subgroup, an
adjusted Cox model was fitted to obtain the hazard ratio and P-value for the weight gain group comparison. The controlling covariates that were included in
the models were age, gender, histology, ECOG performance status, disease stage, BMI, smoking history, and study. The covariate used to select the patient sub-
group to be analyzed was excluded in the adjusted Cox model. BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; NonSqu/Nonadeno/NOS,
non-squamous/non-adenocarcinoma/not otherwise specified histology; PS, performance status.
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in the 20–25 BMI (ideal weight range), >25 BMI (overweight),
and <20 BMI (approaching underweight). The low BMI sub-
group is noteworthy because these individuals may have already
experienced cachexia-induced weight loss or have comorbidities
that interfere with weight gain. The high BMI weight group is
also interesting in that they did as well as the ideal BMI weight
group. Given that proinflammatory cytokines including TNFα
and IL-6 are secreted by adipose tissue, this similar outcome of
the high and ideal BMI groups suggests that mechanisms
other than inflammatory cytokines may be involved in weight
loss [22].
The adjusted Cox modeling showed that after adjusting for
other covariates, patients with high (>25) baseline BMI had a
statistically significant longer OS and PFS. A recently published
analysis has investigated the impact of baseline BMI and weight
loss on OS [24]. In the absence of pretreatment weight loss data
in our studies, we carried out an exploratory analysis investigat-
ing the impact of baseline BMI and post-baseline weight gain on
OS. The results show that baseline BMI and post-baseline
weight gain are significant predictors for OS, after adjusting for
other baseline covariates. Particularly, the group of BMI >25
and weight gain >5% had significantly longer median OS com-
pared with other BMI and weight gain groups. Interestingly,
a recent analysis of ECOG trials also showed an association of
high BMI (≥30, obese) with longer survival relative to a com-
bined group of normal weight (18.5–25 BMI) and overweight
(>25–30 BMI) patients [25]. The ECOG trial analysis also
observed that the ≥30 BMI subgroup exhibited a significant in-
crease in OS HR relative to the normal/overweight subgroup
when time on study exceeded 16 months.
The analyses presented here are retrospective and thus would
benefit from confirmation by additional prospective studies. An
additional limitation of these analyses was the absence of data
regarding the percentage of weight loss each patient had experi-
enced before study therapy. These data would clarify if the
patients who gained weight were the same as those who experi-
enced pretreatment weight loss. If pretreatment weight loss
correlated with on-treatment weight gain, this finding could
support the hypothesis that longer survival was at least in part
the result of reversing cachexia. Our data were also limited and
potentially skewed because the analyses did not factor in that
patients with progressive disease discontinue from study treat-
ment earlier than those who have stable or responding disease.
Patient drop out would give the stable/responding patients more
time on study in which to gain weight and thus magnify the
contribution of weight gain on treatment outcome. Finally, our
analyses did not separate the high BMI subgroup into obese
(≥30) and overweight (≥25–30 BMI) groupings. Doing so in
future analyses will allow further observation of subgroup trends
while enabling and accounting for the larger weight gain neces-
sary for the obese population to achieve a 5% weight gain.
Serial weight measurement is a readily accomplished assessment.
If additional prospective studies confirm weight gain as prognostic
for survival, its assessment will provide an additional tool for the
treating physician. Stable or increasing weight might be cause to
continue with the treatment regimen; conversely, declining weight
might alert the physician to the need for a different therapeutic ap-
proach. While serial weight measurement will not replace NSCLC
tumor assessment as the definitive measure of treatment efficacy,
stable or increasing weight may be practical indicators of clinical
benefit related to tumor control and treatment tolerability.
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The role of oral hygiene in head and neck cancer: results
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Background: Poor oral hygiene has been proposed to contribute to head and neck cancer (HNC) risk, although causal-
ity and independency of some indicators are uncertain. This study investigates the relationship of five oral hygiene indica-
tors with incident HNCs.
Methods: In a pooled analysis of 8925 HNC cases and 12 527 controls from 13 studies participating in the International
Head and Neck Cancer Epidemiology Consortium, comparable data on good oral hygiene indicators were harmonized.
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